Please use this identifier to cite or link to this item:
|Title:||Radioimmunotherapy of Breast Cancer Metastases with Alpha-Particle-emitter 225Ac: Comparing Efficacy with 213Bi, 90Y|
|Authors:||SONG Hong; HOBBS Robert F.; VAJRAVELU Ravy; HUSO David L.; ESAIAS Caroline; APOSTOLIDIS Christos; MORGENSTERN Alfred; SGOUROS George|
|Citation:||CANCER RESEARCH vol. 69 no. 23 p. 8941-8948|
|Publisher:||AMER ASSOC CANCER RESEARCH|
|Type:||Articles in periodicals and books|
|Abstract:||Alpha-particles are suitable to treat cancer micrometastases because of their short range and very high linear energy transfer. Alpha-particle-emitter 213Bi based radioimmunotherapy has shown efficacy in a variety of metastatic animal cancer models, such as breast, ovarian, prostate cancer and leukemia. Its clinical implementation, however, is challenging due to the limited supply of 225Ac, the high technical requirement to prepare radioimmunoconjugate with very short half-life (T1/2=45.6 mins) on site and prohibitive cost. In this study, we investigated the efficacy of the alpha-particle emitter 225Ac, parent of 213Bi, in a mouse model of breast cancer metastases. A single administration of 225Ac (400 nCi) labeled anti-rat HER-2/neu monoclonal antibody (7.16.4) completely eradicated breast cancer lung micrometastases in about 67% of HER-2/neu transgenic mice and led to long-term survival of these mice for up to one year. Treatment with 225Ac-7.16.4 is significantly more effective than 213Bi-7.16.4 (120 µCi) (median survival = 61 days, P=0.001), and 90Y-7.16.4 (120 µCi) (median survival = 50 days, P<0.001), as well as untreated control (median survival = 41 days, P=0.0001). Dosimetric analysis showed that 225Ac treated metastases received a total dose of 9.6 Gy, significantly higher than 2.0 Gy from 213Bi and 2.4 Gy from 90Y. Biodistribution studies revealed that 225Ac daughters, 221Fr and 213Bi, accumulated in kidneys and probably contributed to the long-term renal toxicity observed in surviving mice. These data suggest 225Ac labeled anti-HER-2/neu monoclonal antibody could significantly prolong survival in HER-2/neu-positive metastatic breast cancer patients.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.